ANU Medical School, College of Health and Medicine, Australian National University, Canberra, Australia.
Community and Patient Preference Research, Sydney, Australia.
J Dermatolog Treat. 2024 Dec;35(1):2339440. doi: 10.1080/09546634.2024.2339440. Epub 2024 Jul 30.
Oral systemic and injectable biologic treatments are available in Australia to treat moderate to severe psoriasis.
To examine how patients and dermatologists in Australia choose between oral and injectable treatments for psoriasis.
In this discrete choice experiment (DCE), adults with moderate to severe psoriasis and dermatologists were asked to choose between 2 treatments labeled by mode of administration ('oral' or 'subcutaneous injection'), each with randomly assigned levels for 9 treatment attributes. Needle fear was rated by patients.
Completed surveys from 178 patients and 43 dermatologists were included in the analysis. Symptom reduction, safety, and mode of administration were attributes found to have a significant impact on treatment choice; dosing frequency was a significant attribute for the injectable option. When treatment attributes were held equal, patients and dermatologists preferred oral versus injectable treatments for moderate disease. Patients with higher levels of needle fear were more likely to favor an oral treatment versus patients with lower levels of needle fear.
Participation bias may limit the generalizability of these findings.
Participants preferred oral over injectable treatment for moderate psoriasis. These findings corroborate the need for efficacious oral therapies to treat the disease.
在澳大利亚，有口服和注射用生物制剂可用于治疗中重度银屑病。
研究澳大利亚的患者和皮肤科医生如何在银屑病的口服和注射治疗之间进行选择。
在这项离散选择实验（DCE）中，中重度银屑病患者和皮肤科医生被要求在两种治疗方法（“口服”或“皮下注射”）之间进行选择，每种治疗方法都有 9 种治疗属性的随机分配水平。患者对针恐惧进行了评分。
共纳入了 178 名患者和 43 名皮肤科医生的完成调查进行分析。症状缓解、安全性和给药方式是对治疗选择有显著影响的属性；对于注射选择，给药频率是一个重要的属性。当治疗属性相同时，患者和皮肤科医生更倾向于选择口服治疗而非注射治疗中度疾病。针恐惧程度较高的患者比针恐惧程度较低的患者更倾向于选择口服治疗。
参与偏见可能限制这些发现的普遍性。
参与者更倾向于口服治疗而非注射治疗中度银屑病。这些发现证实了需要有效的口服疗法来治疗这种疾病。
